...
首页> 外文期刊>JAMA neurology >Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial
【24h】

Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial

机译:与Rivaroxaban的复发性卒中与阿司匹林相比,根据心房颤动的预测因子进行了患者的心房颤动的二级分析,随机临床试验

获取原文
获取原文并翻译 | 示例
           

摘要

IMPORTANCE The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it substantially reduces stroke risk in patients with atrial fibrillation (AF).
机译:重要性该导航ESUS随机临床试验发现,与栓塞中风患者的栓塞症患者(ESUS)的患者中,每天15毫克Rivaroxaban不会减少中风; 然而,它基本上降低了心房颤动患者的卒中风险(AF)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号